GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Zymeworks Inc.
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. Its stock price is volatile and depends on the results of clinical trials and partnerships with major pharmaceutical companies that validate its technology platform.
Share prices of companies in the market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. This is its core segment. We classify it as part of the Oncology Immunotherapy sector, and the chart below reflects the dynamics of this cutting-edge biotech field.
Broad Market Index - GURU.Markets
Zymeworks is a Canadian biotech company developing bispecific antibodies and other multifunctional drugs for cancer treatment. It is a component of the GURU.Markets index. The chart below shows the US market. See how Zymeworks shares compare to the US market trend.
Change in the price of a company, segment, and market as a whole per day
ZYME - Daily change in the company's share price Zymeworks Inc.
Daily fluctuations in Zymeworks, a biotech company developing antibodies for cancer treatment, reflect the risks and expectations of the sector. Change_co measures sensitivity to research news. This metric is the basis for immunotherapy sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Zymeworks Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with ZYME's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Zymeworks is a biopharmaceutical company developing bispecific antibodies for cancer treatment. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this sector, helping to assess the risks and dynamics of Zymeworks stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Zymeworks Inc.
Zymeworks is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Zymeworks Inc. is a biotech company developing bispecific antibodies and other immunotherapies for cancer treatment. Its stock price reflects both the potential of its scientific platform and the risks associated with clinical trials, which is typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Zymeworks is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Zymeworks Inc.
The performance of Zymeworks, a biotech company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials of its bispecific antibodies for cancer treatment, as well as partnerships with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing bispecific antibodies and conjugates for cancer treatment. Its value is driven by progress in clinical trials and partnerships. The immuno-oncology sector performance chart reflects the overall investor appetite for breakthrough treatments, which provides an important backdrop for assessing Zymeworks' scientific platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps broader market trends. The chart below shows the pulse of the broader market. Does Zymeworks move in sync with it, or are breakthroughs in its R&D pipeline creating a completely independent story for the stock?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Zymeworks Inc.
Zymeworks, a biotech company developing bispecific antibodies for cancer treatment, is experiencing high volatility. Weekly stock performance is driven by clinical trial data, partnership news, and regulatory decisions, reflecting the risks and potential of innovative oncology.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Zymeworks, like other biotech companies specializing in oncology, exhibits high volatility. The chart allows you to compare its performance with the sector to see how much of its movements are driven by general sentiment and how much by specific news about its drugs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Zymeworks is a biotech company developing multifunctional antibodies for cancer treatment. Its shares exist in a world of their own, where research data is king. The chart shows that Zyme's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
ZYME - Market capitalization of the company Zymeworks Inc.
Zymeworks' market cap is a financial roadmap of innovation in bispecific antibody development. This biotech company's chart reflects its belief in its platforms for creating next-generation cancer drugs. Its dynamics are a barometer of its partnerships with major pharma and progress in clinical trials, where any outcome could change the valuation of its technology.
ZYME - Share of the company's market capitalization Zymeworks Inc. within the market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing a new generation of multifunctional antibodies for cancer treatment. Its market capitalization reflects the potential of its Azymetric and ZymeLink technology platforms. The chart below shows how the market views its innovative approach to creating more effective oncology drugs.
Market capitalization of the market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing a new generation of bispecific antibodies for cancer treatment. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investor hopes for breakthroughs in targeted cancer therapy.
Market capitalization of all companies included in a broad market index - GURU.Markets
Zymeworks is a biotech company developing a new generation of bispecific antibodies for cancer treatment. Its market capitalization chart tells the story of the search for more precise and effective methods to combat cancer. Its dynamics reflect progress in clinical trials and investor expectations.
Book value capitalization of the company, segment and market as a whole
ZYME - Book value capitalization of the company Zymeworks Inc.
For Zymeworks, a biotech company, book value is its capital and laboratory equipment. The chart below shows financial and scientific resources, not manufacturing facilities. Its dynamics reflect the successes and failures of raising funding for the development of innovative cancer drugs.
ZYME - Share of the company's book capitalization Zymeworks Inc. within the market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing a new generation of cancer drugs. Its main asset is its scientific platform. The company's share of tangible assets will be low, reflecting its focus on R&D, with laboratories rather than large manufacturing facilities.
Market segment balance sheet capitalization - Oncology immuno-therapy
Zymeworks is a biotech company developing next-generation antibodies for cancer treatment. Its key asset is its unique scientific platform and development pipeline. A book value chart shows that its value is based on intangible assets rather than manufacturing assets, which is typical for innovative oncology companies.
Book value of all companies included in the broad market index - GURU.Markets
Zymeworks is a platform for creating bispecific antibodies. The company's assets consist of advanced laboratories, intellectual property for its technologies, and capital for clinical trials. The chart shows the size of its resource base, aimed at developing a new class of drugs for cancer treatment.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Zymeworks Inc.
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. Its book value is primarily cash. Its market capitalization reflects the valuation of its unique scientific platform, Azymetric, and the potential of its drug candidates, as well as its partnerships with major pharmaceutical companies.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Zymeworks Inc. is a biotech company developing multispecific antibodies for cancer treatment. Its core value is its scientific platform and development pipeline. The chart shows the market premium for its innovative approaches compared to the cost of its laboratory equipment.
Market to book capitalization ratio for the market as a whole
Zymeworks is a biotech company developing multifunctional drugs for cancer treatment. Its value lies in its scientific platform and development pipeline. The market is evaluating the potential for developing a new class of drugs. The chart clearly demonstrates how investors are willing to pay a premium for breakthrough technologies in oncology.
Debts of the company, segment and market as a whole
ZYME - Company debts Zymeworks Inc.
For Zymeworks, a biotech company developing bispecific antibodies, debt is a crucial source of research funding. This chart shows the company's funding to advance its oncology drug candidates through clinical trials. This represents an investment in a complex scientific platform with the potential to create a new class of drugs.
Market segment debts - Oncology immuno-therapy
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. In immuno-oncology, one of the most competitive areas of biotech, funding clinical trials requires significant resources. The chart shows how Zymeworks' debt strategy compares to its extensive and expensive research portfolio.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Zymeworks Inc.
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. This complex technology requires long-term and significant investments in R&D. This chart shows how the company manages its balance sheet. Its low debt load allows it to flexibly manage its development pipeline and enter into favorable partnerships.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Zymeworks is a biotech company developing bispecific antibodies and conjugates for cancer treatment. Its platform technologies are attracting partners. This chart shows the overall debt burden in the sector. It helps assess how Zymeworks uses both partner fees and debt to fund its ambitious R&D programs.
Debt to book value of all companies in the market
Zymeworks, a biotech company with an innovative platform, relies on partnerships and funding. This chart shows the overall market leverage. It helps assess how macroeconomic conditions affect the ability of large pharmaceutical companies (Zymeworks' partners) to invest in risky R&D, which directly impacts the company's business.
P/E of the company, segment and market as a whole
P/E - Zymeworks Inc.
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. This chart reflects investor confidence in its scientific platform. The indicator's performance is heavily dependent on news about clinical trials. Successful data could trigger a sharp increase, as it confirms the technology's potential for creating a new class of drugs.
P/E of the market segment - Oncology immuno-therapy
Zymeworks is a biotech company in the oncology sector. This chart shows the average P/E for the industry. Comparing the company's P/E to this benchmark allows us to understand how disruptive investors consider its bispecific antibody platform compared to technologies being developed by other biotech companies.
P/E of the market as a whole
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. Its platform enables the creation of drugs that attack cancer cells more effectively. The company's valuation depends on the success of its developments. This chart shows the overall interest in oncology. It helps us understand whether Zymeworks' technology stands out from the competition and how the market views its potential.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Zymeworks Inc.
Zymeworks is a biotech company developing next-generation, multifunctional therapeutics for cancer treatment. This chart reflects investor expectations for its bispecific antibody platform. The company's valuation is based on clinical success projections and potential partnerships with major pharmaceutical companies.
%20P%2FE%20Zymeworks%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Zymeworks-Inc.&v=1772513471379 "Chart of the company's future (projected) P/E Zymeworks Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing bispecific antibodies and conjugates for cancer treatment. This chart compares Zymeworks' future profitability expectations with those of the oncology sector. It demonstrates the level of investor confidence in its scientific platform and key clinical programs, as well as the value of its partnerships with major pharmaceutical companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772513471431 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Zymeworks is a biotech company developing next-generation, multifunctional therapeutics for cancer treatment. Funding for innovative oncology research is highly dependent on the overall risk appetite of investors. This chart, showing market sentiment, serves as a barometer of this appetite, determining Zymeworks' ability to raise capital.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513471472 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Zymeworks Inc.
Zymeworks is a biotech company developing multifunctional drugs for cancer treatment. Its financial health is determined by partnerships with large pharmaceutical companies, which provide funding for its research. This chart illustrates the financial model, where upfront and milestone payments from partners support costly clinical development.
Profit of companies in the market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing bispecific antibodies and other multifunctional therapeutics for cancer treatment. This graph, which shows the sector's total revenue, highlights the complexity and potential of immuno-oncology. The success of Zymeworks' platform and its clinical candidates could lead to new treatment standards and impact the entire industry.
Overall market profit
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. Its innovative platform enables the creation of drugs that attack tumors more effectively. The company's value is determined by the progress of its clinical programs, making it independent of general market trends and dependent on scientific breakthroughs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Zymeworks Inc.
Zymeworks is a biotech company developing multifunctional antibodies for cancer treatment. The future revenue projections you see are closely tied to clinical trial results and partnerships with major pharmaceutical companies. Analyst expectations reflect the potential of its innovative platforms for the development of new oncology drugs.
%20profit%20of%20the%20company%20Zymeworks%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Zymeworks-Inc.&v=1772513471618 "Graph of future (projected) profit of the company Zymeworks Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing multifunctional drugs for cancer treatment. Its platforms enable the creation of drugs that target multiple targets simultaneously. This chart shows revenue forecasts for the immuno-oncology segment, allowing one to assess how the company's innovative approach compares to overall financial expectations for this competitive field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772513471634 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Zymeworks is a biotech company developing multispecific antibodies for cancer treatment. Its shares are driven by news of clinical developments. However, the overall investment climate, reflected in this chart, is important. Optimistic economic forecasts are driving capital inflows into the high-risk but potentially high-reward biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513471660 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Zymeworks Inc.
Zymeworks Inc. is a biotech company developing a new generation of multifunctional antibodies for cancer treatment. This chart, plotting market capitalization against revenue (primarily from partnerships), reflects the valuation of its scientific platform. It shows the premium investors are paying for the potential of its innovative approaches to creating more effective drugs.
P/S market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing a new generation of multifunctional biotherapeutics for cancer treatment. Its platforms enable the creation of drugs that can attack cancer cells in multiple ways. This chart shows how investors value revenue in the oncology sector, demonstrating the level of confidence in Zymeworks' innovative technology platforms.
P/S of the market as a whole
Zymeworks Inc. is a clinical-stage biopharmaceutical company developing bispecific antibodies and antibody-drug conjugates for the treatment of cancer. Its Azymetric and ZymeLink platforms enable the creation of multifunctional drugs. This chart helps understand how the market evaluates the potential of innovative oncology platforms compared to average market performance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Zymeworks Inc.
Zymeworks is a biotech company developing a new generation of multifunctional antibodies for cancer treatment. This chart shows investor estimates of its potential future drug revenue. It reflects the market's confidence in its technology platform and clinical trial success, as well as its partnerships with major pharmaceutical companies.
%20P%2FS%20Zymeworks%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Zymeworks-Inc.&v=1772513471821 "The graph of the company's future (projected) P/S Zymeworks Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Zymeworks is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics for the treatment of cancer. This chart compares investor expectations for its future revenue with the sector. The valuation reflects investor opinion on the potential of its proprietary Azymetric and ZymeLink platforms to create more effective oncology treatments.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772513471835 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Zymeworks is a biotech company developing bispecific antibodies and conjugates for cancer treatment. Its platform enables the creation of more effective targeted drugs. This market expectations chart reflects investor confidence that innovative approaches in oncology will lead to the creation of a new generation of drugs and significant revenue growth.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513471877 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Zymeworks Inc.
This chart illustrates Zymeworks' partnership-based business model. While in the clinical stage of cancer drug development, the company generates revenue not from sales, but from upfront and milestone payments from large pharmaceutical companies licensing its technologies. This growth reflects the success of its research and the value of its developments.
Sales of companies in the market segment - Oncology immuno-therapy
Zymeworks is a biotechnology company developing a new generation of multifunctional drugs, primarily bispecific antibodies, for the treatment of cancer. The company's platforms enable the creation of innovative drugs. This graph represents the total revenue of the entire oncology drug market, illustrating the commercial potential of Zymeworks' cutting-edge technologies.
Overall market sales
Zymeworks Inc. is a biotech company developing bispecific antibodies for cancer treatment. Its value is determined by progress in clinical trials and partnerships. The overall economic environment, shown in this chart, influences the investment climate in the biotech sector, which affects the company's ability to finance its long-term projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Zymeworks Inc.
Zymeworks is a biotech company developing multifunctional drugs for the treatment of cancer. Its future revenue depends on the success of clinical trials and strategic partnerships. This chart reflects analysts' long-term expectations for the commercial potential of its bispecific antibodies and antibody-drug conjugates.
%20sales%20of%20the%20company%20Zymeworks%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Zymeworks-Inc.&v=1772513472001 "Schedule of future (projected) sales of the company Zymeworks Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Zymeworks is a biopharmaceutical company developing multifunctional therapeutics for the treatment of cancer. The forecast in this chart reflects the potential future revenue from their key developments and partnerships. The data shows which of their innovative platforms and drugs, according to analysts, have the greatest commercial potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772513472018 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
This chart, reflecting investment appetite in biotech, is important for Zymeworks. The company is developing bispecific antibodies for cancer treatment. Funding for its extensive research program depends on partnerships with major pharmaceutical companies and capital raising, which is easier to achieve in a climate of positive economic expectations.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513472033 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Zymeworks Inc.
Zymeworks is a clinical-stage biotech company developing multifunctional antibodies for cancer treatment. This graph reflects significant investments in research and development. Future profitability depends on the success of clinical trials of its innovative platforms and partnerships with major pharmaceutical companies.
Market segment marginality - Oncology immuno-therapy
Zymeworks is a biotech company developing a new generation of multispecific antibodies for cancer treatment. Profitability depends on the success of its bispecific platforms in clinical trials and partnerships. This chart shows the average profitability in the pharmaceutical industry and provides context for assessing the potential of Zymeworks' innovative approaches.
Market marginality as a whole
Zymeworks is a biotech company developing multifunctional therapeutics for cancer treatment. Its value and prospects depend on the success of its clinical trials. This chart reflects the overall sentiment of investors and their willingness to fund risky but potentially breakthrough projects in oncology, which determines the company's future.
Employees in the company, segment and market as a whole
Number of employees in the company Zymeworks Inc.
Zymeworks Inc. is a biotechnology company developing multifunctional antibodies for cancer treatment. This chart reflects the size of the company's scientific and clinical development team. Changes in the chart may reflect a focus on the most promising programs and partnerships, which require optimization of R&D resources to achieve success.
Share of the company's employees Zymeworks Inc. within the market segment - Oncology immuno-therapy
Zymeworks is developing a new generation of multifunctional antibodies for cancer treatment. Its platforms enable the creation of highly effective drugs. This chart shows the company's share of the total number of scientists working on bispecific antibodies. This reflects its technological leadership and innovative potential in oncology.
Number of employees in the market segment - Oncology immuno-therapy
Zymeworks Inc. is a biopharmaceutical company developing next-generation, multifunctional therapeutics for cancer treatment. This chart reflects activity in the immuno-oncology sector. The growing number of scientists in this highly competitive field reflects the intensive search for more effective and targeted treatments, which is the core of Zymeworks' innovation platform.
Number of employees in the market as a whole
Zymeworks is a biotech company developing multifunctional therapeutics for the treatment of cancer. Their value and growth are driven by clinical trial data and partnerships. This overall employment chart does not apply to these clinical trials. Hiring dynamics at Zymeworks are driven by scientific progress and the need for specialists to advance research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Zymeworks Inc. (ZYME)
Zymeworks is a biotech company developing multifunctional therapeutics for cancer treatment. Its value lies in its proprietary platforms and pipeline. This chart shows how the market values its scientific innovations. A small team of scientists creates intellectual property with enormous potential.
%20of%20the%20company%20Zymeworks%20Inc.%20(ZYME)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Zymeworks-Inc.-ZYME&v=1772513472196 "Chart of market capitalization per employee (in thousands of dollars) of the company Zymeworks Inc. (ZYME)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. Their platform (Azymetric) enables the creation of smart drugs. The company's value lies in its R&D platform and partnerships. This chart shows how the market values their scientific developments.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772513472221 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Zymeworks is a biotech company developing multifunctional antibodies for cancer treatment. Its value is driven by the innovativeness of its scientific platform. This chart shows a very high market valuation per employee, as investors are betting on the technology to create more effective drugs developed by a focused scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513472241 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Zymeworks Inc. (ZYME)
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. This involves complex protein engineering. This chart reflects their focus on R&D: it shows how much the company spends (negative profit) on each scientist to create and test these innovative oncology drugs, although some of the costs can be covered through partnerships.
%20Chart%20Zymeworks%20Inc.%20(ZYME)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Zymeworks-Inc.-ZYME&v=1772513472273 "Company Profit Per Employee (in thousands of dollars) Chart Zymeworks Inc. (ZYME)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Zymeworks is a clinical-stage biotech company developing "bi-specific" "antibodies" (immunotherapy) for the treatment of "cancer." This chart shows the benchmark for the "Biotech sector." In this industry, the average profit per employee is typically deeply negative. The benchmark is determined not by "profit," but by the "burn rate" of the R&D budget.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772513472299 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. Their platforms (Azymetric, Zymelink) enable the creation of smarter drugs. This is a complex R&D process. This chart shows how the model, based on a breakthrough scientific platform and led by a team of elite researchers, differs in terms of efficiency per employee compared to the market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513472333 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Zymeworks Inc. (ZYME)
Zymeworks is a biotech company developing multifunctional therapeutics for cancer treatment. Its revenue per employee comes primarily from upfront fees from partnerships with major pharmaceutical companies. This chart shows these revenues, which are vital to funding its extensive R&D activities.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Zymeworks-Inc.-ZYME&v=1772513472339 "Sales chart per company employee Zymeworks Inc. (ZYME)")
Sales per employee in the market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing bispecific antibodies (which can attack two targets simultaneously) for cancer treatment. This is cutting-edge protein engineering. This chart reflects their R&D status. Revenue comes primarily from major partnerships (such as with Johnson & Johnson), and the productivity of their scientists is focused on creating new drug candidates.
Sales per employee for the market as a whole
Zymeworks (ZYME) is a biotech company developing multifunctional therapeutics (e.g., bispecific antibodies) for the treatment of cancer. They have several drugs in clinical development. This chart for R&D-stage biotechs reflects partnership revenue. Zymeworks receives large upfront and milestone payments from partners (e.g., Jazz, BeiGene), which fund their large scientific staff.
Short shares by company, segment and market as a whole
Shares shorted by company Zymeworks Inc. (ZYME)
Zymeworks is a biotech company developing bispecific antibodies and antibody-drug conjugates (ADCs) for cancer treatment. They use their Azymetric and ZymeLink platforms. This chart shows the level of skepticism. Bears may doubt the competitiveness of their platform compared to other ADC developers or bet on potential failures in key clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Zymeworks-Inc.-ZYME&v=1772513472420 "Short Shares Chart for the Company Zymeworks Inc. (ZYME)")
Shares shorted by market segment - Oncology immuno-therapy
Zymeworks (ZYME) is a biotech company developing multispecific antibodies for cancer treatment. Their Azymetric platform enables the creation of complex drugs. This chart shows bets against the immuno-oncology sector. Shorts in this sector reflect the general investor skepticism toward platforms that have not yet proven their commercial viability and the intense competition.
Shares shorted by the overall market
Zymeworks (ZYME) is a clinical-stage biotech (oncology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives ZYME of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Zymeworks Inc. (ZYME)
Zymeworks is a biotech company developing bispecific antibodies for cancer treatment. The stock is volatile and dependent on R&D. A chart reading above 70 may reflect positive trial or partnership data. Oversold territory (<30) is often associated with research setbacks or a general downturn in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Zymeworks-Inc.-ZYME&v=1772513472473 "RSI 14 indicator chart for the company's stock Zymeworks Inc. (ZYME)")
RSI 14 Market Segment - Oncology immuno-therapy
Zymeworks is a biopharmaceutical company developing a new generation of bispecific antibodies for cancer treatment. Its platforms (Azymetric) enable the creation of more precise treatments. This chart shows the overall "temperature" in the volatile immuno-oncology sector. It helps separate ZYME's performance from the general hype or disillusionment in the field.
RSI 14 for the overall market
Zymeworks (ZYME) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ZYME (Zymeworks Inc.)
Zymeworks (ZYME) is a biotech company that developed the Azymetric and ZymeLink platforms for creating bispecific antibodies and antigen-conjugate (ADC) conjugates for cancer treatment. This chart shows the average analyst forecast. It reflects their assessment of the value of these platforms and the success of the key drug, zanidatamab, developed in partnership with Jazz Pharmaceuticals.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ZYME-Zymeworks-Inc.&v=1772513472571 "A chart showing analyst consensus forecasts for the expected stock price. ZYME (Zymeworks Inc.)")
The difference between the consensus estimate and the actual stock price ZYME (Zymeworks Inc.)
Zymeworks is a Canadian biotech company developing bispecific antibodies. Its platforms (Azymetric) create smart drugs that attack cancer from two angles simultaneously. This chart shows the difference between the consensus forecast and the price. It reflects the analysts' confidence in Zymeworks' science and R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ZYME-Zymeworks-Inc.&v=1772513472715 "A chart showing the difference between the consensus forecast and the actual stock price. ZYME (Zymeworks Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Zymeworks is a biotech company developing multifunctional antibodies and antibody-drug conjugates (ADCs) for the treatment of complex cancers. This chart shows analysts' overall expectations for the immunotherapy sector, reflecting their confidence in the potential of their Aymura platform.
Analysts' consensus forecast for the overall market share price
Zymeworks is a clinical-stage biotech developing bispecific antibodies for cancer treatment. It's a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with high potential. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Zymeworks Inc.
Zymeworks is a biotech company developing bispecific antibodies—complex drugs that can attack cancer cells from two directions simultaneously. This is the cutting edge of immuno-oncology. This chart is an assessment of their R&D platform. Its dynamics reflect the results of their clinical trials and their partnerships with major pharma, which licenses their technology.
AKIMA Market Segment Index - Oncology immuno-therapy
Zymeworks (ZYME) is a clinical-stage biotech focused on oncology; the company is developing an innovative bispecific antibody platform (which attacks cancer from two angles) in partnership with J&J. This composite metric evaluates R&D companies. The graph shows the average value for the segment. This is a benchmark: how does this technological R&D platform (ZYME) differentiate itself from the average pharma company?
The AKIM Index for the overall market
Zymeworks is a biotech company developing multifunctional biotherapeutics (antibodies) for cancer treatment. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this R&D operation, dependent on partnerships with big pharma, compares to overall economic trends and risk appetite.
